2196.HK
2196.HK
CNE100001M79
FOSUN PHARMA
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 65/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±44.4% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.4x).

Beta (Market Relation)
0.38x
Defensive
Volatility (5Y p.a.)
44.4% p.a.
5-Year Horizon
Max Drawdown (5Y)
-74.0%
5-Year Horizon
Sharpe Ratio
-0.37
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -29.9%
3 Years 40.2% -47.7% -0.05 +0.5%
5 Years 44.4% -74.0% -0.37 -13.4%
10 Years 46.5% -85.2% -0.12 -3.3%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (44.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -85.2% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
3 ISS Score: 3 / 10
Audit Risk
4 ISS Score: 4 / 10
Board Risk
4 ISS Score: 4 / 10
Short Ratio
-
ende